atezolizumab + lenalidomide

Atezolizumab + lenalidomide is an **investigational drug combination** involving atezolizumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), and lenalidomide, an immunomodulatory small molecule. The combination leverages atezolizumab's ability to block PD-L1-mediated immune evasion by tumor cells and lenalidomide's various immunostimulatory actions, including T-cell and NK-cell activation via cereblon-mediated degradation of transcription factors (Ikaros, Aiolos) and suppression of pro-inflammatory cytokines. This combination has been studied for synergistic anti-tumor immunomodulation, notably in relapsed/refractory follicular lymphoma and previously in multiple myeloma, though with significant safety concerns observed in the latter setting[1][3][5].